nitric oxide  novan show nav please enable javascript for a better site experience novan presents preclinical data from sb program posters presentations provide mechanistic evidence for sb as a potential treatment for psoriasis and atopic dermatitis novan reports topline results with sb in phase  trial sb a potential broadspectrum antifungal gel for the treatment of infections of the skin and nails novan reshapes executive management team paula brown stafford appointed chief development officer stanley hollenbach promoted to senior vp of rd phase  results with sb to be presented at  aad annual meeting sb a firstinclass topical antiviral gel in clinical development for the treatment of viral skin infections novan licenses sb to sato for acne in japan novan inc is a latestage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the company’s nitric oxide platform our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated firstinclass product candidates we are rapidly advancing programs in five dermatological conditions with significant unmet medical need we believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market learn more about novan press releases july  novan announces corporate update conference call and webcast  july  novan to present safety and efficacy data for sb program in adolescents at th world congress of pediatric dermatology june  novan announces leadership adjustments and business update in the news july  novan acne gel found safe in three clinical trials july  nitric oxidebased acne treatment effective in adolescents with acne vulgaris july  nitric oxide cream in pipeline close close novan  senior leadership show nav senior leadership kevin barbervp of regulatory affairs kevin barber ms phd rac pmp is vice president of regulatory affairs and leads the development and execution of novan’s regulatory strategy  dr barber has over  years of experience in pharmaceutical product development and biomedical research with a background in designing and implementing effective integrated regulatory plans  most recently dr barber served as vice president of global brand regulatory affairs at actavis formerly watson pharmaceuticals where he was responsible for regulatory development of over  products and regulatory life cycle management of more than  approved products in us canadian and european markets  william l hodgesinterim chief financial officer william l hodges cpa is the interim chief financial officer most recently mr hodges was chief financial officer and senior vice president of finance and administration for pozen inc where he was part of the team that led to the development and commercialization of vimovo® treximet® and yosprala™ in february  pozen completed the acquisition of tribute pharmaceuticals canada inc along with a  million commitment from leading healthcare capital partners to form a premier specialty pharmaceutical company aralez pharmaceuticals inc previously mr hodges held numerous progressive roles in finance including vice president corporate planning and business support at glaxowellcome before being appointed acting senior vice president and chief financial officer for the fifteen months leading up to the glaxosmithkline merger in  stan hollenbachsenior vp of research and development stan hollenbach bs jd is the senior vice president of research and development and leads all phases of pharmaceutical drug development other than clinical testing of novan’s product candidates mr hollenbach has more than  years of experience in the biotechnology industry specializing in preclinical development of small molecules and proteins which included participation in numerous us and european regulatory submissions prior to joining novan in  mr hollenbach was the vice president of pharmacology at portola pharmaceuticals inc where he focused primarily on platelet and fibrin mediated thrombosis leading the preclinical development of orally bioavailable antiplatelet py antagonists and the factor xa inhibitors andexanet alpha and betrixaban he also worked previously at cor therapeutics which was acquired by millennium pharmaceuticals and genetech as well as served in the us army at the letterman army institute of research lair with research experience in emergency care and resuscitative therapy of combat casualties jeff n huntervp of technical operations jeff n hunter ms is the vice president of technical operations and has been integral to the company’s execution and operational success since its inception  with more than  years of broad business experience including as cofounder and former ceo and chairman of a smallcap public company mr hunter has built novan’s corporate infrastructure systems as well as strengthened supply chain and business relationships  his versatility and indepth understanding of the company’s business encompass manufacturing and product development  in  the triangle business journal recognized mr hunter as a top executive in his field  in  he was appointed to serve on the board of directors of the north carolina biotechnology center brian johnsonchief commercial officer brian johnson is the chief commercial officer responsible for novan’s commercialization efforts including sales marketing and managed care for the company’s dermatology products  mr johnson brings to novan nearly three decades of marketing and sales leadership at dermatology companies including ortho pharmaceutical corporation johnson  johnson’s dermatological division medicis pharmaceutical corporation and galderma laboratories llc where he served as vice president of prescription marketing and chief digital officer  at galderma he and his team quadrupled sales by launching category leaders like epiduo® clobex® and oracea®  in addition to epiduo® he participated in the sales andor marketing of other leading acne brands including retina® dynacin® and differin®    g kelly martinchief executive officer g kelly martin is chief executive officer of novan inc mr martin also serves at the chief executive officer of malin life sciences holding  he served as ceo of elan ireland’s largest indigenous biotech company from february  until its successful  billion sale to perrigo company in december   before joining elan mr martin spent more than  years at merrill lynch  co inc where he held a broad array of operating and executive responsibilities  mr martin also serves as a nonexecutive director on a number of public and private company boards and is a cofounder and director of brandon point industries paula brown staffordchief development officer paula brown stafford mph is the chief development officer and leads the tactical execution of clinical trials and the establishment of statistics and data management functions for novan most recently ms stafford served as president of clinical development at quintiles now quintilesims where she was responsible for all phase iiv clinical development operations globally reaching  billion in annual revenue during her time at quintiles ms stafford was also a member of the quintiles executive committee for more than five years and founded quintiles enterprise data council and quintiles women inspired network ms stafford serves as a director at health decisions inc and adjunct professor in public health leadership at the gillings school of global public health at the university of north carolina at chapel hill additionally she provides executive solutions and coaching through her consulting firm habergeon llc ms stafford was a  recipient of the triangle business journal’s women in business award and named as one of the  top women in biotech by fiercebiotech in  nathan staskopresident  chief scientific officer nathan stasko phd is cofounder president and chief scientific officer and a director of novan inc dr stasko has led the transformation of the company’s nitric oxide platform from the academic benchtop to phase  clinical trials and is considered a leading expert in the field of nitric oxide he is an inventor of the core novan technology and of more than  patent filings  of which have issued and has authored several peerreviewed manuscripts pertaining to the chemical storage and controlled release of nitric oxide dr stasko has led the company through each of its private financings totaling more than  million as well as the award of government grants and contracts totaling  million the latter ultimately resulting in novan’s national recognition as a tibbetts award winner for excellence in small business innovation research he has assembled a team of highly experienced executives and skilled professionals with drug development and commercialization expertise who share his vision to position novan as a commercially successful leader in the dermatology market about novansenior leadershipboard of directorsadvisory councilcareerscontact close close novan  company overview show nav overview novan inc is a latestage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the company’s nitric oxide platform nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a pipeline of differentiated firstinclass product candidates we are rapidly advancing programs in five dermatological conditions with significant unmet medical need we believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market the two key components of our nitric oxide platform are our proprietary nitricil™ technology which drives the creation of new chemical entities or nces and our topical formulation science both of which we use to modulate or “tune” our product candidates for specific indications for more about nitric oxide nitricil or our product candidates please visit the technology and product pipeline sections of our website about novansenior leadershipboard of directorsadvisory councilcareerscontact close close novan  contact us show nav contact usnovan  hopson roadmorrisville north carolina phone fax  investorsinvestorsnovancom mediadeb hollidaypascale communications llc on behalf of novandebpascalecommunicationscom send us a message if you are interested in business development for nitric oxidebased products please fill in the information below  required information first name  last name  email address  companyaffiliation  title  city  country  phone number  i am interested in exploring the following opportunities with novan business developmentinvestmentlicensingresearch collaboration please tell me more about nitric oxides potential in cardiovascularcentral nervous systemdermatologyinfectious diseaseinflammatory disordersoncologyoral carepulmonarywound care comments please type the letters and numbers shown in the image click the image to see another captcha  about novansenior leadershipboard of directorsadvisory councilcareerscontact follow us linkedin twitter youtube close close novan  sb show nav onychomycosis onychomycosis is a chronic fungal infection of the nails that affects approximately  million americans the infection caused by dermatophytes such as trichophyton rubrum often results in painful thickening and deformation of the nail and sometimes separation of the nail plate from the nail bed leading to an inability of the nail to perform its natural protective function oral therapies used to treat the infection are associated with severe side effects and topical therapies have modest efficacy profiles with complete cure rates of less than  sb novan is developing sb as a broadspectrum antifungal gel for the treatment of superficial cutaneous fungal infections of the skin and nails such as tinea pedis and onychomycosis in a phase  clinical trial sb gel at both the  and  concentrations demonstrated a statistically significant effect p compared to vehicle in a clinical trial in patients with tinea pedis or athlete’s foot clinical data in the primary efficacy analysis of patients with evaluable culture results  p of patients treated with sb  and  p of patients treated with sb  achieved negative fungal culture at day  versus  of patients treated with vehicle the percentage of patients achieving mycological cure at the day  visit was  p of the patients treated with sb  and  p of patients treated with sb  versus  of patients treated with vehicle mycological cure was maintained at day  in both dose groups  of patients treated with sb  demonstrated a mycological cure compared to vehicle p preclinical data in the chubtur® infected human nail assay a model utilized previously in the drug development of kerydin® tavaborole topical solution  and jublia® efinaconazole topical solution  nitric oxidereleasing formulations demonstrated rapid penetration of the nail and effective fungal killing of t rubrum in  hours following a single treatment application clinical trial clinicaltrialsgov identifier nct all trademarks are the property of their respective owners close close novan  board of directors show nav board of directors robert a ingramexecutive chairman robert ingram has served on novan’s board of directors since  and was named chairman in february   mr ingram is a general partner of hatteras venture partners  prior to hatteras venture partners he held the roles of chief executive officer and chairman of the board of glaxowellcome until his retirement in  when he became strategic advisor to the chief executive officer glaxosmithkline plc nysegsk  mr ingram has numerous board engagements including lead director of valeant pharmaceuticals international nasdaqvrx and chairman of viamet pharmaceuticals inc  he is also a member of the board of directors of malin corporation plc dublinmlc and biocryst pharmaceuticals inc nasdaqbcrx and  lead director of cree inc nasdaqcree    w kent geerlead independent director w kent geer is a former audit partner retired with ernst  young llp  his  year career spans an extensive track record in serving numerous public and private companies in a variety of industries including biotechnology pharmaceuticals and other technology companies  during his tenure mr geer was the audit practice leader for the ernst  young entrepreneurial services group in raleigh north carolina and was the market team leader for the technology industry practice of the carolinas  beginning in  mr geer served as the chairman of the board of powersecure international inc nysepowr until the successful sale of the company in may  robert j keegan robert keegan is the former chief executive officer and chairman of the board of the goodyear tire  rubber company roles that he held until his retirement in   most recently he was an operating partner of the san franciscobased private equity firm friedman fleischer  lowe  from  to  mr keegan held various marketing financial and managerial posts at eastman kodak except for a twoyear period from  to  when he worked as an executive vice president of the avery dennison corporation mr keegan is chairman of the board of loparex inc serves on the boards of the xerox corporation nyse xrx and fuqua business school and the heart center of duke university and is a partner of lk properties of north carolina llc g kelly martin g kelly martin is chief executive officer of malin life sciences holding  he served as ceo of elan ireland’s largest indigenous biotech company from february  until its successful  billion sale to perrigo company in december   before joining elan mr martin spent more than  years at merrill lynch  co inc where he held a broad array of operating and executive responsibilities  mr martin also serves as a nonexecutive director on a number of public and private company boards and is a cofounder and director of brandon point industries sean murphy sean murphy is a nonexecutive director of malin life sciences holding and the former head of corporate ma and business development at abbott laboratories  he is also a senior adviser at evercore partners a leading investment banking advisory firm in a career that spans over thirty years mr murphy’s experience in the life sciences sector is both operational and transactional having run abbott’s vascular business and played a leading role in a number of strategic investments during his tenure   mr murphy is also a director of brandon point industries and immucor  mr murphy is a cpa state of illinois john palmour dr palmour is a cofounder the chief technology officer power  rf and a vice president of cree inc dr palmour has authored or coauthored more than  publications and is a coinventor on  us patents and  corresponding foreign patents he has been a program manager or principal investigator on government research contracts to cree totaling more than  million having served as a member of the board of directors of cree for fifteen years dr palmour has extensive experience and expertise in advancing innovation to broadscale product commercialization nathan stasko dr stasko is a cofounder president and chief executive officer and a director of novan inc dr stasko has led the transformation of the company’s nitric oxide platform from the academic benchtop to phase  clinical trials and is considered a leading expert in the field of nitric oxide he is an inventor of the core novan technology and of more than  patent filings  of which have issued and has authored several peerreviewed manuscripts pertaining to the chemical storage and controlled release of nitric oxide dr stasko has led the company through each of its private financings totaling more than  million as well as the award of government grants and contracts totaling  million the latter ultimately resulting in novan’s national recognition as a tibbetts award winner for excellence in small business innovation research he has assembled a team of highly experienced executives and skilled professionals with drug development and commercialization expertise who share his vision to position novan as a commercially successful leader in the dermatology market about novansenior leadershipboard of directorsadvisory councilcareerscontact close close novan  sb show nav acne vulgaris acne vulgaris is the most common skin condition in the us affecting approximately  million to  million americans annually  the disease ranges in severity from mild to severe cystic acne and causes both physical and psychological effects including permanent scarring anxiety depression and poor selfesteem  the complexity of the disease requires treatments that address more than one of the major causes of acne pathogenesis sb sb the company’s lead drug candidate for the treatment of acne vulgaris is in late stage clinical development we believe that sb has the potential to redefine the standard of care in acne vulgaris and if approved will be the first new chemical entity specifically developed for the treatment of acne vulgaris in more than  years  sb clinical trial results statistically significant efficacy with sb  when compared to vehicle in both inflammatory and noninflammatory lesion endpoints clear separation between active and vehicle good cutaneous tolerability once daily treatment that is noninferior to twice daily no measureable systemic exposure under maximal use conditions in adults or adolescents with moderatetosevere acne clinicaltrialsgov identifier nct     close close novan inc  product pipeline review       gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  biotechnology  general biotechnology novan inc  product pipeline review   published feb  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample   global markets direct’s ‘novan inc product pipeline review ’ provides an overview of the novan inc’s pharmaceutical research and development focus   this report provides comprehensive information on the current therapeutic developmental pipeline of novan inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects   global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis   the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products   scope   the report provides brief overview of novan inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of novan inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the novan inc’s pipeline products   reasons to buy   evaluate novan inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of novan inc in its therapy areas of focus identify new drug targets and therapeutic classes in the novan inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of novan inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of novan inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of novan inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents   table of contents  list of tables  list of figures  novan inc snapshot  novan inc overview  key information  key facts  novan inc  research and development overview  key therapeutic areas  novan inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  novan inc  pipeline products glance  novan inc  clinical stage pipeline products  phase ii productscombination treatment modalities  novan inc  early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  novan inc  drug profiles  sb  product description  mechanism of action  rd progress  cr  product description  mechanism of action  rd progress  nvn  product description  mechanism of action  rd progress  sb  product description  mechanism of action  rd progress  small molecule for chronic wounds and burns  product description  mechanism of action  rd progress  novan inc  pipeline analysis  novan inc  pipeline products by route of administration  novan inc  pipeline products by molecule type  novan inc  recent pipeline updates  novan inc  locations and subsidiaries  head office    appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer    list of tables   novan inc key information  novan inc key facts  novan inc  pipeline by indication   novan inc  pipeline by stage of development   novan inc  monotherapy products in pipeline   novan inc  phase ii   novan inc  preclinical   novan inc  discovery   novan inc  pipeline by route of administration   novan inc  pipeline by molecule type   novan inc  recent pipeline updates     list of figures   novan inc  pipeline by top  indication   novan inc  pipeline by stage of development   novan inc  monotherapy products in pipeline   novan inc  pipeline by top  route of administration   novan inc  pipeline by top  molecule type   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports united states plant extracts market by manufacturers states type and application forecast to  jul  global info research  pages    code  mrs   plant extracts is a kind of matter which extracts from the plant or the parts of plant by the suitable solvent or methods it can used to the pharmaceutical industry food industry healthy industry beauty industry and other industries scope of the report this report focuses on the plant extracts in united states market to split the market based on manufacturers states type and application market segment by manufacturers this report covers indena network schw read more world tuberculin market research report  covering usa europe china japan india south east asia and etc jul  icrworld research  pages    code  mrs   summary icrworld’s tuberculin market research report provides the newest industry data and industry future trends allowing you to identify the products and end users driving revenue growth and profitability the industry report lists the leading competitors and provides the insights strategic industry analysis of the key factors influencing the market the report includes the forecasts analysis and discussion of important industry trends market size market share estimates and profiles read more world mobile devices biometrics market research report  jul  icrworld research  pages    code  mrs   summary icrworld’s mobile devices biometrics market research report provides the newest industry data and industry future trends allowing you to identify the products and end users driving revenue growth and profitability the industry report lists the leading competitors and provides the insights strategic industry analysis of the key factors influencing the market the report includes the forecasts analysis and discussion of important industry trends market size market share estimate read more europe pet insurance market by manufacturers countries type and application forecast to  jul  global info research  pages    code  mrs   this report studies the pet insurance market pet insurance is a type of specialty property and casualty insurance policy that pet owners purchase to cover the unintended costs that arise in providing care for a pet including veterinary services such as surgical procedures injuries from accidents and prescribed pet medicines pet insurance is purely a reimbursement program a form of property and casualty insurance pet insurance provides reimbursement to the owner after the pet has rece read more europe dental software market  estimation  forecast  jun  market research future  pages    code  mrs   introduction dental software is a computer technology used by dental professionals dental laboratories dental academic and research institutes for diagnosis prevention treatment research and investigation of oral health conditions the europe dental software market is expected to reach usd  million by  at a cagr of  during the forecast period on the basis of countries europe dental software market is divided read more global north america europe and asiapacific south america middle east and africa mesenchymal stem cells market  forecast to  jul  global info research  pages    code  mrs   mesenchymal stem cells msc also termed mesenchymal stromal cells are multipotent cells that can differentiate into a variety of cell types and have the capacity for selfrenewal scope of the report this report focuses on the mesenchymal stem cells in global market especially in north america europe and asiapacific south america middle east and africa this report categorizes the market based on manufacturers regions type and application market segment by manufacturers read more global mobile healthcare device industry market research  jun  hjresearch  pages    code  mrs   in this report we analyze the mobile healthcare device industry from two aspects one part is about its production and the other part is about its consumption in terms of its production we analyze the production revenue gross margin of its main manufacturers and the unit price that they offer in different regions from  to  in terms of its consumption we analyze the consumption volume consumption value sale price import and export in different regions from  to  we read more global nutricosmetics industry market research  jun  hjresearch  pages    code  mrs   in this report we analyze the nutricosmetics industry from two aspects one part is about its production and the other part is about its consumption in terms of its production we analyze the production revenue gross margin of its main manufacturers and the unit price that they offer in different regions from  to  in terms of its consumption we analyze the consumption volume consumption value sale price import and export in different regions from  to  we also make read more global vascular dopplers industry market research  jun  hjresearch  pages    code  mrs   in this report we analyze the vascular dopplers industry from two aspects one part is about its production and the other part is about its consumption in terms of its production we analyze the production revenue gross margin of its main manufacturers and the unit price that they offer in different regions from  to  in terms of its consumption we analyze the consumption volume consumption value sale price import and export in different regions from  to  we also ma read more global cosmeceuticals industry market research  jun  hjresearch  pages    code  mrs   in this report we analyze the cosmeceuticals industry from two aspects one part is about its production and the other part is about its consumption in terms of its production we analyze the production revenue gross margin of its main manufacturers and the unit price that they offer in different regions from  to  in terms of its consumption we analyze the consumption volume consumption value sale price import and export in different regions from  to  we also make read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports novan inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports novan inc  product pipeline review   novan inc  product pipeline review   wgr  february  global  pages global markets direct description table of content sample report enquiry before buy related reports novan inc  product pipeline review  summaryglobal markets direct’s ‘novan inc  product pipeline review  ’ provides an overview of the novan inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of novan inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of novan inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of novan inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the novan inc’s pipeline productsreasons to buy evaluate novan inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of novan inc in its therapy areas of focus identify new drug targets and therapeutic classes in the novan inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of novan inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of novan inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of novan inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures novan inc snapshot novan inc overview key information key facts novan inc  research and development overview key therapeutic areas novan inc  pipeline review pipeline products by stage of development pipeline products  monotherapy novan inc  pipeline products glance novan inc  clinical stage pipeline products phase ii productscombination treatment modalities novan inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities novan inc  drug profiles sb product description mechanism of action rd progress cr product description mechanism of action rd progress nvn product description mechanism of action rd progress sb product description mechanism of action rd progress small molecule for chronic wounds and burns product description mechanism of action rd progress novan inc  pipeline analysis novan inc  pipeline products by route of administration novan inc  pipeline products by molecule type novan inc  recent pipeline updates novan inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesnovan inc key information novan inc key facts novan inc  pipeline by indication  novan inc  pipeline by stage of development  novan inc  monotherapy products in pipeline  novan inc  phase ii  novan inc  preclinical  novan inc  discovery  novan inc  pipeline by route of administration  novan inc  pipeline by molecule type  novan inc  recent pipeline updates  list of figuresnovan inc  pipeline by top  indication  novan inc  pipeline by stage of development  novan inc  monotherapy products in pipeline  novan inc  pipeline by top  route of administration  novan inc  pipeline by top  molecule type   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send novan inc private company information  bloomberg july    am et pharmaceuticals company overview of novan inc snapshot people company overview novan inc a clinicalstage drug development company focuses on the development and commercialization of nitric oxidebased therapies in dermatology its lead product candidate is sb a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris the company’s product candidates also include sb sb and sb which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology the company has a license agreement with sato pharmaceutical co ltd novan inc was founded in  and is headquartered in morrisville north carolina  hopson roadmorrisville nc united statesfounded in  employees phone  fax  wwwnovantherapeuticscom key executives for novan inc dr nathan stasko phd cofounder president chief scientific officer  director age  total annual compensation k mr brian johnson chief commercial officer age  total annual compensation k compensation as of fiscal year  novan inc key developments novan inc announces management changes jun   effective june   nathan stasko formerly the president and chief executive officer of novan inc has transitioned to the role of president and chief scientific officer of the company and g kelly martin currently serving on the companys board of directors has been appointed to serve as the companys chief executive officer on an interim basis effective with this transition mr martin has stepped down from the compensation committee of the board following the appointment of a chief executive officer of the company subsequent to mr martins appointment as chief executive officer on an interim basis and upon request of the board dr stasko has agreed to resign from his positions as either president or as a director of the company or both as requested novan inc reports unaudited consolidated earnings results for the first quarter ended march   may   novan inc reported unaudited consolidated earnings results for the first quarter ended march   for the quarter the company reported license and collaboration revenue of  operating loss was  compared to  a year ago net loss and comprehensive loss was  or loss of  per basic and diluted share compared to  or loss of  per basic and diluted share a year ago novan inc announces resignation of joyce rico as chief medical officer may   on may   m joyce rico chief medical officer of novan inc notified the company of her decision to resign on may   the company and dr rico reached agreement regarding her departure from the company effective may   similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact novan inc please visit wwwnovantherapeuticscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close novan inc  product pipeline review    acute market reports about us contact us sitemap home our services market research reports business consulting prolonge business leverages plan your own research industry reports country reports press release login register home  healthcare  novan inc  product pipeline review   novan inc  product pipeline review   published feb   no of pages   published by global markets direct report summary     table of content     list of tables     list of figures     request sample novan inc  product pipeline review   summary global markets directs novan inc  product pipeline review   provides an overview of the novan incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of novan incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of novan inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of novan incs human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the novan incs pipeline products reasons to buy  evaluate novan incs strategic position with total access to detailed information on its product pipeline  assess the growth potential of novan inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the novan incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of novan inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of novan inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of novan inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  novan inc snapshot  novan inc overview  key information  key facts  novan inc  research and development overview  key therapeutic areas  novan inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  novan inc  pipeline products glance  novan inc  clinical stage pipeline products  phase ii productscombination treatment modalities  novan inc  early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  novan inc  drug profiles  sb  product description  mechanism of action  rd progress  cr  product description  mechanism of action  rd progress  nvn  product description  mechanism of action  rd progress  sb  product description  mechanism of action  rd progress  small molecule for chronic wounds and burns  product description  mechanism of action  rd progress  novan inc  pipeline analysis  novan inc  pipeline products by route of administration  novan inc  pipeline products by molecule type  novan inc  recent pipeline updates  novan inc  locations and subsidiaries  head office  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  novan inc key information  novan inc key facts  novan inc  pipeline by indication   novan inc  pipeline by stage of development   novan inc  monotherapy products in pipeline   novan inc  phase ii   novan inc  preclinical   novan inc  discovery   novan inc  pipeline by route of administration   novan inc  pipeline by molecule type   novan inc  recent pipeline updates   novan inc  pipeline by top  indication   novan inc  pipeline by stage of development   novan inc  monotherapy products in pipeline   novan inc  pipeline by top  route of administration   novan inc  pipeline by top  molecule type   choose license type single user   multi user   enterprise   buy now   contact information  research support phone  salesacutemarketreportscom get in touch with us join us on facebook follow us on twitter follow us on linkedin add us on google  home about us customer faq how to order privacy policy terms of use  copyright  acute market reports and its affiliates all rights reserved newsletter sign up signup for latest updates  promos send payment options contact us acute market reports office no  st floor  aditi mall baner pune mh  india toll freeuscanada  india   salesacutemarketreportscom novan inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report novan inc  product pipeline review   published by global markets direct product code  published february   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license novan inc  product pipeline review   published february   content info  pages description summary global markets directs novan inc  product pipeline review   provides an overview of the novan incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of novan incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of novan inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of novan incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the novan incs pipeline products reasons to buy evaluate novan incs strategic position with total access to detailed information on its product pipeline assess the growth potential of novan inc in its therapy areas of focus identify new drug targets and therapeutic classes in the novan incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of novan inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of novan inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of novan inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures novan inc snapshot novan inc overview key information key facts novan inc  research and development overview key therapeutic areas novan inc  pipeline review pipeline products by stage of development pipeline products  monotherapy novan inc  pipeline products glance novan inc  clinical stage pipeline products phase ii productscombination treatment modalities novan inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities novan inc  drug profiles sb product description mechanism of action rd progress cr product description mechanism of action rd progress nvn product description mechanism of action rd progress sb product description mechanism of action rd progress small molecule for chronic wounds and burns product description mechanism of action rd progress novan inc  pipeline analysis novan inc  pipeline products by route of administration novan inc  pipeline products by molecule type novan inc  recent pipeline updates novan inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables novan inc key information novan inc key facts novan inc  pipeline by indication  novan inc  pipeline by stage of development  novan inc  monotherapy products in pipeline  novan inc  phase ii  novan inc  preclinical  novan inc  discovery  novan inc  pipeline by route of administration  novan inc  pipeline by molecule type  novan inc  recent pipeline updates  list of figures novan inc  pipeline by top  indication  novan inc  pipeline by stage of development  novan inc  monotherapy products in pipeline  novan inc  pipeline by top  route of administration  novan inc  pipeline by top  molecule type  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports related reports head and neck cancer  pipeline review h  published may   alchemia ltd  product pipeline review   published dec   array biopharma inc  product pipeline review   published dec   bionomics ltd  product pipeline review   published dec   chong kun dang pharmaceutical corp  product pipeline review   published dec   csl ltd  product pipeline review   published dec   genervon biopharmaceuticals llc  product pipeline review   published dec   genethon sa  product pipeline review   published dec   hutchison medipharma ltd  product pipeline review   published dec   hyundai pharmaceutical co ltd  product pipeline review   published dec   ▼ about contact user guide policies site map  copyright  global information inc all rights reserved novan  company overview show nav overview novan inc is a latestage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the company’s nitric oxide platform nitric oxide plays a vital role in the natural immune system response against microbial pathogens and is a critical regulator of inflammation our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a pipeline of differentiated firstinclass product candidates we are rapidly advancing programs in five dermatological conditions with significant unmet medical need we believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market the two key components of our nitric oxide platform are our proprietary nitricil™ technology which drives the creation of new chemical entities or nces and our topical formulation science both of which we use to modulate or “tune” our product candidates for specific indications for more about nitric oxide nitricil or our product candidates please visit the technology and product pipeline sections of our website about novansenior leadershipboard of directorsadvisory councilcareerscontact close close novan inc  novn  stock price today  zacks free gift for zackscom visitors novn is up  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more novan inc novn delayed data from nsdq  usd     updated jul    pm et premarket     am et add to portfolio zacks rank hold          style scores f value  f growth  f momentum  f vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank bottom  out of  industry medical  drugs view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  drugs zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for novn all zacks’ analyst reports news for novn zacks news for novn other news for novn why novan novn could be positioned for a surge am est zacks novan novn shares march higher can it continue am est zacks novn what are zacks experts saying now zacks private portfolio services will  ipo market revive after dismal  pm est zacks more zacks news for novn novan announces leadership adjustments and business update am est gurufocus novan reports first quarter ¿¿¿¿¿¿¿¿¿ financial results am est gurufocus novan reports q results am est seeking alpha novan misses by  am est seeking alpha short interest makes  move for novn pm est market news video more other news for novn premium research for novn zacks rank hold  zacks industry rank bottom  out of  zacks sector rank bottom   out of  style scores f value  f growth  f momentum  f vgm earnings esp  research report for novn snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank novan inc novn alcobra ltd adhd consort medical plc sponsored adr csrmy immune design corp imdz advanced accelerator applications sa aaap aerie pharmaceuticals inc aeri clinigen gp plc cligf see all medical  drugs peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary novan inc is a pharmaceutical company it engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology the companys product candidates primarily include sb sb sb and sb which are in preclinical trial stage it develops product through nitricil technologytm novan inc is based in durham united states microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates robot check enter the characters you see below sorry we just need to make sure youre not a robot for best results please make sure your browser is accepting cookies type the characters you see in this image try different image continue shopping conditions of use privacy policy   amazoncom inc or its affiliates amazoncom amazon music unlimited interesting finds updated daily amazon try prime digital music all departments alexa skills amazon devices amazon video amazon warehouse deals appliances apps  games arts crafts  sewing automotive parts  accessories baby beauty  personal care books cds  vinyl cell phones  accessories clothing shoes  jewelry    women    men    girls    boys    baby collectibles  fine art computers courses credit and payment cards digital music electronics gift cards grocery  gourmet food handmade health household  baby care home  business services home  kitchen industrial  scientific kindle store luggage  travel gear luxury beauty magazine subscriptions movies  tv musical instruments office products patio lawn  garden pet supplies prime exclusive prime pantry software sports  outdoors tools  home improvement toys  games vehicles video games wine go departments en   hello sign inaccount  listssign inaccount  listsorderstry primecart your amazoncomtodays dealsgift cards  registrysellhelpdisability customer support amazon music unlimited prime music cds  vinyl download store open web player mp cart settings mo for prime members nonprime price month change or cancel anytime start your day free trial mo for prime members nonprime price month change or cancel anytime start your day free trial mo for prime members nonprime price month change or cancel anytime start your day free trial any song anywhere tens of millions of songs with new releases from todays most popular artists listen adfree with unlimited skips download for offline listening any song anywhere tens of millions of songs with new releases from todays most popular artists listen adfree with unlimited skips download for offline listening any song anywhere tens of millions of songs with new releases from todays most popular artists listen adfree with unlimited skips download for offline listening already using prime music upgrade to amazon music unlimited now to unlock tens of millions of songs including the hottest new releases only month or year  months for the price of  already using prime music upgrade to amazon music unlimited now to unlock tens of millions of songs including the hottest new releases only month or year  months for the price of  already using prime music upgrade to amazon music unlimited now to unlock tens of millions of songs including the hottest new releases only month or year  months for the price of  better with echo  just ask play your favorite music with innovative alexa voice controls exclusive to amazon music want amazon music unlimited just on your echo learn more better with echo  just ask play your favorite music with innovative alexa voice controls exclusive to amazon music want amazon music unlimited just on your echo learn more better with echo  just ask play your favorite music with innovative alexa voice controls exclusive to amazon music want amazon music unlimited just on your echo learn more choose the right amazon music plan for you learn more learn more learn more questions see our faq start free trial choose the right amazon music plan for you learn more learn more learn more questions see our faq start free trial choose the right amazon music plan for you learn more learn more learn more questions see our faq start free trial theres a problem loading this menu right now learn more about amazon prime get fast free shipping with amazon prime prime members enjoy free twoday shipping and exclusive access to music movies tv shows original audio series and kindle books  get started v